Trial Profile
Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept in Patients With Exudative Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Apr 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Pharmacodynamics
- 20 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Sep 2014 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Jul 2014 New trial record